Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1987 Jul;61(7):2120–2127. doi: 10.1128/jvi.61.7.2120-2127.1987

Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs.

A Weinberg, M Konrad, T C Merigan
PMCID: PMC254232  PMID: 3035213

Abstract

The goal of our study was to determine whether recombinant interleukin-2 (rIL-2) could modify the recurrence pattern of chronic herpes simplex virus type 2 (HSV-2) genital infection in guinea pigs. Animals that developed symptomatic acute HSV-2 infection were distributed at 14 days after viral inoculation into several treatment groups, which were similar with respect to the severity of acute disease. Three rIL-2 dosages administered for 4 weeks in daily subcutaneous injections were tested in this study: 5 X 10(3), 5 X 10(4), and 2.5 X 10(5) U. Daily observations of the animals showed a significant decrease of the incidence of new recurrent lesions with the use of 5 X 10(4) U of rIL-2 (rate of recurrence, 0.08, compared with 0.21 in untreated controls), whereas the other rIL-2 regimens did not affect the overall rate of recurrence. Weekly analysis of recurrences showed that treatment with 5 X 10(4) U of rIL-2 was effective only during the first 3 weeks of use and that 2.5 X 10(5) U of rIL-2 markedly decreased the rate of recurrence in the first week of treatment but not in subsequent weeks. The loss of clinical protection in both groups coincided with the production of neutralizing antibodies to rIL-2. The immune mechanisms possibly involved in the protective effect of rIL-2 in chronic HSV-2 disease were further investigated. Production of gamma interferon correlated well with clinical protection, and circulating levels dropped at the time when neutralizing antibodies to rIL-2 developed. Nonspecific cytotoxicity represented by natural killer cell and lymphokine-activated killer cell activities was also increased in the treated guinea pigs. Antibody titers and lymphocyte proliferation to herpes simplex antigen were similar in rIL-2 and placebo recipients. Finally, we found that the rIL-2-induced immune stimulation was as protective against recurrent HSV-2 disease in guinea pigs as the viral suppression achieved with acyclovir. However, the biological activity of both drugs was not additive when they were coadministered.

Full text

PDF
2120

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andriole G. L., Mulé J. J., Hansen C. T., Linehan W. M., Rosenberg S. A. Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice. J Immunol. 1985 Nov;135(5):2911–2913. [PubMed] [Google Scholar]
  2. Corey L., Nahmias A. J., Guinan M. E., Benedetti J. K., Critchlow C. W., Holmes K. K. A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med. 1982 Jun 3;306(22):1313–1319. doi: 10.1056/NEJM198206033062201. [DOI] [PubMed] [Google Scholar]
  3. Cunningham A. L., Merigan T. C. gamma Interferon production appears to predict time of recurrence of herpes labialis. J Immunol. 1983 May;130(5):2397–2400. [PubMed] [Google Scholar]
  4. Domke I., Straub P., Jacobsen H., Kirchner H., Panet A. Inhibition of replication of herpes simplex virus in mouse macrophages by interferons. J Gen Virol. 1985 Oct;66(Pt 10):2231–2236. doi: 10.1099/0022-1317-66-10-2231. [DOI] [PubMed] [Google Scholar]
  5. Domzig W., Stadler B. M., Herberman R. B. Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol. 1983 Apr;130(4):1970–1973. [PubMed] [Google Scholar]
  6. Douglas J. M., Critchlow C., Benedetti J., Mertz G. J., Connor J. D., Hintz M. A., Fahnlander A., Remington M., Winter C., Corey L. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med. 1984 Jun 14;310(24):1551–1556. doi: 10.1056/NEJM198406143102402. [DOI] [PubMed] [Google Scholar]
  7. Elion G. B., Furman P. A., Fyfe J. A., de Miranda P., Beauchamp L., Schaeffer H. J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5716–5720. doi: 10.1073/pnas.74.12.5716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ellis M. N., Barry D. W. Oral acyclovir therapy of genital herpes simplex virus type 2 infections in guinea pigs. Antimicrob Agents Chemother. 1985 Feb;27(2):167–171. doi: 10.1128/aac.27.2.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ennis F. A., Martin W. J., Verbonitz M. W. Hemagglutinin-specific cytotoxic T-cell response during influenza infection. J Exp Med. 1977 Sep 1;146(3):893–898. doi: 10.1084/jem.146.3.893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Farrar J. J., Benjamin W. R., Hilfiker M. L., Howard M., Farrar W. L., Fuller-Farrar J. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunol Rev. 1982;63:129–166. doi: 10.1111/j.1600-065x.1982.tb00414.x. [DOI] [PubMed] [Google Scholar]
  11. Farrar W. L., Johnson H. M., Farrar J. J. Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. J Immunol. 1981 Mar;126(3):1120–1125. [PubMed] [Google Scholar]
  12. Gillis S., Watson J. Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line. J Exp Med. 1980 Dec 1;152(6):1709–1719. doi: 10.1084/jem.152.6.1709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hefeneider S. H., Conlon P. J., Henney C. S., Gillis S. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol. 1983 Jan;130(1):222–227. [PubMed] [Google Scholar]
  15. Henney C. S., Kuribayashi K., Kern D. E., Gillis S. Interleukin-2 augments natural killer cell activity. Nature. 1981 May 28;291(5813):335–338. doi: 10.1038/291335a0. [DOI] [PubMed] [Google Scholar]
  16. Herberman R. R., Ortaldo J. R., Bonnard G. D. Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature. 1979 Jan 18;277(5693):221–223. doi: 10.1038/277221a0. [DOI] [PubMed] [Google Scholar]
  17. Kasahara T., Hooks J. J., Dougherty S. F., Oppenheim J. J. Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol. 1983 Apr;130(4):1784–1789. [PubMed] [Google Scholar]
  18. Kawamura H., Rosenberg S. A., Berzofsky J. A. Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness. J Exp Med. 1985 Jul 1;162(1):381–386. doi: 10.1084/jem.162.1.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kawase I., Brooks C. G., Kuribayashi K., Olabuenaga S., Newman W., Gillis S., Henney C. S. Interleukin 2 induces gamma-interferon production: participation of macrophages and NK-like cells. J Immunol. 1983 Jul;131(1):288–292. [PubMed] [Google Scholar]
  20. Kern E. R. Acyclovir treatment of experimental genital herpes simplex virus infections. Am J Med. 1982 Jul 20;73(1A):100–108. doi: 10.1016/0002-9343(82)90073-0. [DOI] [PubMed] [Google Scholar]
  21. Koff W. C., Fidler I. J., Showalter S. D., Chakrabarty M. K., Hampar B., Ceccorulli L. M., Kleinerman E. S. Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells. Science. 1984 Jun 1;224(4652):1007–1009. doi: 10.1126/science.6426057. [DOI] [PubMed] [Google Scholar]
  22. Lafreniere R., Rosenberg S. A. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. 1985 Aug;45(8):3735–3741. [PubMed] [Google Scholar]
  23. Landry M. L., Lucia H. L., Hsiung G. D., Pronovost A. D., Dann P. R., August M. J., Mayo D. R. Effect of acyclovir on genital infection with herpes simplex virus types 1 and 2 in the guinea pig. Am J Med. 1982 Jul 20;73(1A):143–150. doi: 10.1016/0002-9343(82)90080-8. [DOI] [PubMed] [Google Scholar]
  24. Mazumder A., Rosenberg S. A. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med. 1984 Feb 1;159(2):495–507. doi: 10.1084/jem.159.2.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Merigan T. C., Gregory D. F., Petralli J. K. Physical properties of human interferon prepared in vitro and in vivo. Virology. 1966 Aug;29(4):515–522. doi: 10.1016/0042-6822(66)90276-5. [DOI] [PubMed] [Google Scholar]
  26. Merluzzi V. J., Welte K., Savage D. M., Last-Barney K., Mertelsmann R. Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2. J Immunol. 1983 Aug;131(2):806–809. [PubMed] [Google Scholar]
  27. Mindel A., Weller I. V., Faherty A., Sutherland S., Hindley D., Fiddian A. P., Adler M. W. Prophylactic oral acyclovir in recurrent genital herpes. Lancet. 1984 Jul 14;2(8394):57–59. doi: 10.1016/s0140-6736(84)90237-x. [DOI] [PubMed] [Google Scholar]
  28. Morris A. G., Lin Y. L., Askonas B. A. Immune interferon release when a cloned cytotoxic T-cell line meets its correct influenza-infected target cell. Nature. 1982 Jan 14;295(5845):150–152. doi: 10.1038/295150a0. [DOI] [PubMed] [Google Scholar]
  29. Mulé J. J., Shu S., Rosenberg S. A. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol. 1985 Jul;135(1):646–652. [PubMed] [Google Scholar]
  30. Mulé J. J., Shu S., Schwarz S. L., Rosenberg S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984 Sep 28;225(4669):1487–1489. doi: 10.1126/science.6332379. [DOI] [PubMed] [Google Scholar]
  31. Myerson D., Hsiung G. D. Prophylactic and therapeutic treatment with acyclovir of genital herpes in the guinea pig. Proc Soc Exp Biol Med. 1983 Nov;174(2):147–152. doi: 10.3181/00379727-174-41717. [DOI] [PubMed] [Google Scholar]
  32. Nakagawa T., Hirano T., Nakagawa N., Yoshizaki K., Kishimoto T. Effect of recombinant IL 2 and gamma-IFN on proliferation and differentiation of human B cells. J Immunol. 1985 Feb;134(2):959–966. [PubMed] [Google Scholar]
  33. Nakanishi K., Malek T. R., Smith K. A., Hamaoka T., Shevach E. M., Paul W. E. Both interleukin 2 and a second T cell-derived factor in EL-4 supernatant have activity as differentiation factors in IgM synthesis. J Exp Med. 1984 Dec 1;160(6):1605–1621. doi: 10.1084/jem.160.6.1605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. O'Reilly R. J., Chibbaro A., Anger E., Lopez C. Cell-mediated immune responses in patients with recurrent Herpes Simplex infections. II. Infection-associated deficiency of lymphokine production in patients with recurrent herpes labialis or herpes progenitalis. J Immunol. 1977 Mar;118(3):1095–1102. [PubMed] [Google Scholar]
  35. Pearlstein K. T., Palladino M. A., Welte K., Vilcek J. Purified human interleukin-2 enhances induction of immune interferon. Cell Immunol. 1983 Aug;80(1):1–9. doi: 10.1016/0008-8749(83)90088-6. [DOI] [PubMed] [Google Scholar]
  36. Pfizenmaier K., Jung H., Starzinski-Powitz A., Röllinghoff M., Wagner H. The role of T cells in anti-herpes simplex virus immunity. I. Induction of antigen-specific cytotoxic T lymphocytes. J Immunol. 1977 Sep;119(3):939–944. [PubMed] [Google Scholar]
  37. Rasmussen L. E., Jordan G. W., Stevens D. A., Merigan T. C. Lymphocyte interferon production and transformation after Herpes simplex infections in humans. J Immunol. 1974 Feb;112(2):728–736. [PubMed] [Google Scholar]
  38. Rasmussen L., Merigan T. C. Role of T lymphocytes in cellular immune responses during herpes simplex virus infection in humans. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3957–3961. doi: 10.1073/pnas.75.8.3957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Reeves W. C., Corey L., Adams H. G., Vontver L. A., Holmes K. K. Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. N Engl J Med. 1981 Aug 6;305(6):315–319. doi: 10.1056/NEJM198108063050604. [DOI] [PubMed] [Google Scholar]
  40. Rook A. H., Masur H., Lane H. C., Frederick W., Kasahara T., Macher A. M., Djeu J. Y., Manischewitz J. F., Jackson L., Fauci A. S. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest. 1983 Jul;72(1):398–403. doi: 10.1172/JCI110981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Rosenberg G. L., Notkins A. L. Induction of cellular immunity to herpes simplex virus: relationship to the humoral immune response. J Immunol. 1974 Mar;112(3):1019–1025. [PubMed] [Google Scholar]
  42. Rosenberg S. A., Grimm E. A., McGrogan M., Doyle M., Kawasaki E., Koths K., Mark D. F. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984 Mar 30;223(4643):1412–1414. doi: 10.1126/science.6367046. [DOI] [PubMed] [Google Scholar]
  43. Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  44. Rosenberg S. A., Mulé J. J., Spiess P. J., Reichert C. M., Schwarz S. L. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985 May 1;161(5):1169–1188. doi: 10.1084/jem.161.5.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Rouse B. T., Miller L. S., Turtinen L., Moore R. N. Augmentation of immunity to herpes simplex virus by in vivo administration of interleukin 2. J Immunol. 1985 Feb;134(2):926–930. [PubMed] [Google Scholar]
  46. Schaeffer H. J., Beauchamp L., de Miranda P., Elion G. B., Bauer D. J., Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature. 1978 Apr 13;272(5654):583–585. doi: 10.1038/272583a0. [DOI] [PubMed] [Google Scholar]
  47. Scriba M. Recurrent genital Herpes simplex virus (HSV) infection of guinea pigs. Med Microbiol Immunol. 1976 Dec 1;162(3-4):201–208. doi: 10.1007/BF02120998. [DOI] [PubMed] [Google Scholar]
  48. Sheridan J. F., Aurelian L., Donnenberg A. D., Quinn T. C. Cell-mediated immunity to cytomegalovirus (CMV) and herpes simplex virus (HSV) antigens in the acquired immune deficiency syndrome: interleukin-1 and interleukin-2 modify in vitro responses. J Clin Immunol. 1984 Jul;4(4):304–311. doi: 10.1007/BF00915298. [DOI] [PubMed] [Google Scholar]
  49. Stanberry L. R., Kern E. R., Richards J. T., Abbott T. M., Overall J. C., Jr Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis. 1982 Sep;146(3):397–404. doi: 10.1093/infdis/146.3.397. [DOI] [PubMed] [Google Scholar]
  50. Straus S. E., Smith H. A., Brickman C., de Miranda P., McLaren C., Keeney R. E. Acyclovir for chronic mucocutaneous herpes simplex virus infection in immunosuppressed patients. Ann Intern Med. 1982 Mar;96(3):270–277. doi: 10.7326/0003-4819-96-3-270. [DOI] [PubMed] [Google Scholar]
  51. Straus S. E., Takiff H. E., Seidlin M., Bachrach S., Lininger L., DiGiovanna J. J., Western K. A., Smith H. A., Lehrman S. N., Creagh-Kirk T. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. N Engl J Med. 1984 Jun 14;310(24):1545–1550. doi: 10.1056/NEJM198406143102401. [DOI] [PubMed] [Google Scholar]
  52. Stötter H., Rüde E., Wagner H. T cell factor (interleukin 2) allows in vivo induction of T helper cells against heterologous erythrocytes in athymic (nu/nu) mice. Eur J Immunol. 1980 Sep;10(9):719–722. doi: 10.1002/eji.1830100912. [DOI] [PubMed] [Google Scholar]
  53. Torseth J. W., Merigan T. C. Significance of local gamma interferon in recurrent herpes simplex infection. J Infect Dis. 1986 May;153(5):979–984. doi: 10.1093/infdis/153.5.979. [DOI] [PubMed] [Google Scholar]
  54. Trinchieri G., Matsumoto-Kobayashi M., Clark S. C., Seehra J., London L., Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 1984 Oct 1;160(4):1147–1169. doi: 10.1084/jem.160.4.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Tsudo M., Uchiyama T., Uchino H. Expression of Tac antigen on activated normal human B cells. J Exp Med. 1984 Aug 1;160(2):612–617. doi: 10.1084/jem.160.2.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Wagner H., Hardt C., Heeg K., Röllinghoff M., Pfizenmaier K. T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice. Nature. 1980 Mar 20;284(5753):278–278. doi: 10.1038/284278a0. [DOI] [PubMed] [Google Scholar]
  57. Wagner H., Röllinghoff M. T-T-cell interactions during the vitro cytotoxic allograft responses. I. Soluble products from activated Lyl+ T cells trigger autonomously antigen-primed Ly23+ T cells to cell proliferation and cytolytic activity. J Exp Med. 1978 Dec 1;148(6):1523–1538. doi: 10.1084/jem.148.6.1523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Waldmann T. A., Goldman C. K., Robb R. J., Depper J. M., Leonard W. J., Sharrow S. O., Bongiovanni K. F., Korsmeyer S. J., Greene W. C. Expression of interleukin 2 receptors on activated human B cells. J Exp Med. 1984 Nov 1;160(5):1450–1466. doi: 10.1084/jem.160.5.1450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Weigent D. A., Stanton G. J., Johnson H. M. Interleukin 2 enhances natural killer cell activity through induction of gamma interferon. Infect Immun. 1983 Sep;41(3):992–997. doi: 10.1128/iai.41.3.992-997.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Weinberg A., Basham T. Y., Merigan T. C. Regulation of guinea-pig immune functions by interleukin 2: critical role of natural killer activity in acute HSV-2 genital infection. J Immunol. 1986 Nov 15;137(10):3310–3317. [PubMed] [Google Scholar]
  61. Weinberg A., Rasmussen L., Merigan T. C. Acute genital infection in guinea pigs: effect of recombinant interleukin-2 on herpes simplex virus type 2. J Infect Dis. 1986 Jul;154(1):134–140. doi: 10.1093/infdis/154.1.134. [DOI] [PubMed] [Google Scholar]
  62. Weyand C. M., Goronzy J., Dallman M. J., Fathman C. G. Administration of recombinant interleukin 2 in vivo induces a polyclonal IgM response. J Exp Med. 1986 Jun 1;163(6):1607–1612. doi: 10.1084/jem.163.6.1607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Wilton J. M., Ivanyi L., Lehner T. Cell-mediated immunity in Herpesvirus hominis infections. Br Med J. 1972 Mar 18;1(5802):723–726. doi: 10.1136/bmj.1.5802.723. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES